(Calgary, Alberta, May 13, 2015) – Each June, the AADSM Research Committee recognizes outstanding research in dental sleep medicine. This year, Dr. Shouresh Charkhandeh, Zephyr Sleep Technologies’ Chief Dental Officer has been selected as the recipient of the AADSM Clinical Research Award based on the scientific merit of the abstract “An Auto-Titrating Mandibular Positioner: Accuracy in Predicting Oral Appliance Therapy Outcome and Efficacious Mandibular Protrusion”.

In addition, due to the research excellence demonstrated in this abstract, Dr. Charkhandeh has also been selected as the recipient of the AADSM Clinical Excellence Award. Both of these awards will be presented to Dr. Charkhandeh at this year’s AADSM meeting in Seattle. In 2012, Dr. Charkhandeh was the recipient of the AADSM Clinical Research Award for his participation as lead investigator in the clinical trial validating the MATRx technology, which was published the following year in the journal SLEEP.

Based on this award winning research, Zephyr is pleased to announce the acceptance of the following abstracts for presentation at the upcoming international meetings in Denver and Seattle:

American Thoracic Society (ATS) – May 16-19, Denver CO
“Predicting Oral Appliance Therapy Outcome Using an Auto-Adjusting Mandibular Positioner in the Home”. These research findings will be presented by Zephyr’s Chief Medical Officer, Dr. John Remmers in a mini-symposium entitled: Picking Winners. Predicting Response to Treatment of Sleep Disordered Breathing in an Era of Personalized Medicine.

American Academy of Dental Sleep Medicine (AADSM) – June 4-6, Seattle WA
“An Auto-Titrating Mandibular Positioner: Accuracy in Predicting Oral Appliance Therapy Outcome and Efficacious Mandibular Protrusion”. These research findings will be reviewed in an oral presentation by Zephyr’s Chief Dental Officer, Dr. Shouresh Charkhandeh.

Associated Professional Sleep Societies (APSS) – June 6-10, Seattle WA
“Selection of Patients for Oral Appliance Therapy Using an Auto-Adjusting Mandibular Positioner in the Home”. These research findings will be presented by Zephyr’s Chief Medical Officer, Dr. John Remmers.

Dr. John Remmers’ extensive research in the field of sleep medicine has led to a number of products and technologies being used by the industry worldwide to provide continuous positive airway pressure (CPAP) therapy to patients diagnosed with obstructive sleep apnea (OSA). Oral appliance therapy (OAT) has emerged as an effective treatment alternative to CPAP. Until recently, there has been no standard or effective method to determine, in advance and at relatively low cost, which patients will be effectively treated with OAT. Since OAT is frequently requested, Sleep Centers are now compelled to establish programs to effectively manage patients seeking this treatment.

In 2012, Dr. Remmers and his team at Zephyr Sleep Technologies developed the MATRx titration system using remote-controlled mandibular positioner (RCMP) technology. The MATRx system has established a new channel for attended studies in the polysomnographic setting. The single-night test allows for real-time adjustments in mandibular position without disrupting the patient’s sleep and is clinically proven to deliver time to treatment comparable to CPAP. “Understanding a patient’s airway response to mandibular protrusion is a critical component of confidently prescribing and delivering efficacious OAT. MATRx is the only clinically validated method to prospectively determine responders to OAT as well as the efficacious target protrusive position” states Dr. Remmers. “The test’s high predictive accuracy enables dentists to achieve an unprecedented success rate with OAT and fosters strong relationships with treatment providers interested in improving therapeutic outcomes” states Dr. Charkhandeh.

The MATRx system continues to be only device cleared by the FDA to predict therapeutic outcome with a custom-fitted mandibular repositioning appliance (MRA). Today, over 140 Sleep Centers across North America have adopted the MATRx technology as the new standard of care for OSA and have built strong relationships with their dental sleep medicine colleagues. Dr. Patrick Strollo comments, “Remmers and colleagues provide evidence that a single-night titration using a remote controlled mandibular positioner can predict success of oral appliance therapy”. A recent review of oral appliance treatment by the ORANGE-Registry, published in the Journal of Clinical Sleep Medicine, states “Identification of therapeutic protrusion level by this method may help reduce side effects produced by further unnecessary titration”.

Since the first MATRx installation in 2012, the MATRx user community has been asking – When is this technology going to be available in the home? Zephyr is excited to announce the completion of their most recent clinical trial with the next generation device that uses the RCMP technology. The clinical trial included over 150 patients, and demonstrates the feasibility of carrying out a computer-controlled mandibular titration (CCMP) test safely in an unattended setting, with an accuracy comparable to MATRx. This clinical trial data will be presented at the aforementioned meetings in Denver and Seattle. “Now that the clinical trial is complete, we are moving this exciting and new technology into product development. Our next objective is to determine the right clinical setting and industrial design for this truly groundbreaking platform” states Paul Cataford, CEO and co-founder of Zephyr.


Zephyr Sleep Technologies is a privately held product development company that researches, develops, manufactures and sells innovative and scientifically-validated medical devices, therapeutics and technologies to improve sleep. Specializing in sleep-disordered breathing, Zephyr’s technologies include diagnostics, theranostics and therapeutics. Zephyr’s products and technologies are used world-wide by sleep labs, technicians, physicians, dentists, and leading-edge sleep researchers. MATRx was developed by Zephyr and is based on and powered by the proprietary and patented technology known as OATRx. Zephyr is based in Calgary, Alberta.

For more information, please visit zephyrsleep.com:
Zephyr Sleep Technologies

Related Articles

Image MATRx End of Life Notice

Dear valued MATRx customer, The MATRx in-lab was cleared by the Food and Drug Administration (FDA) in March, 2012 and was released in the ...

Read more